array:24 ["pii" => "S2254887419300773" "issn" => "22548874" "doi" => "10.1016/j.rceng.2018.12.010" "estado" => "S300" "fechaPublicacion" => "2019-05-01" "aid" => "1620" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Medicina Interna (SEMI)" "copyrightAnyo" => "2019" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Rev Clin Esp. 2019;219:225-6" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S0014256519300177" "issn" => "00142565" "doi" => "10.1016/j.rce.2018.12.005" "estado" => "S300" "fechaPublicacion" => "2019-05-01" "aid" => "1620" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Medicina Interna (SEMI)" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Rev Clin Esp. 2019;219:225-6" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 21 "formatos" => array:2 [ "HTML" => 13 "PDF" => 8 ] ] "es" => array:10 [ "idiomaDefecto" => true "cabecera" => "Correspondencia" "titulo" => "Bevacizumab intravítreo, ¿está exento de efectos adversos extraoculares?" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "225" "paginaFinal" => "226" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Intravitreal bevacizumab: Is it exempt from adverse extraocular effects?" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "M. Sánchez López, M.A. Navarro Puerto, I. Gutiérrez Morales" "autores" => array:3 [ 0 => array:2 [ "nombre" => "M." "apellidos" => "Sánchez López" ] 1 => array:2 [ "nombre" => "M.A." "apellidos" => "Navarro Puerto" ] 2 => array:2 [ "nombre" => "I." "apellidos" => "Gutiérrez Morales" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2254887419300773" "doi" => "10.1016/j.rceng.2018.12.010" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2254887419300773?idApp=WRCEE" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0014256519300177?idApp=WRCEE" "url" => "/00142565/0000021900000004/v1_201904260611/S0014256519300177/v1_201904260611/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S2254887419300761" "issn" => "22548874" "doi" => "10.1016/j.rceng.2018.12.009" "estado" => "S300" "fechaPublicacion" => "2019-05-01" "aid" => "1631" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Medicina Interna (SEMI)" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Rev Clin Esp. 2019;219:226-7" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "Correspondence" "titulo" => "It is possible to mix insulins in the same syringe?" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "226" "paginaFinal" => "227" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "¿Es posible mezclar insulinas en una misma jeringa?" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "M. González Sevilla, A. de Lorenzo Pinto, R. García Sánchez, C. Ortega Navarro" "autores" => array:4 [ 0 => array:2 [ "nombre" => "M." "apellidos" => "González Sevilla" ] 1 => array:2 [ "nombre" => "A." "apellidos" => "de Lorenzo Pinto" ] 2 => array:2 [ "nombre" => "R." "apellidos" => "García Sánchez" ] 3 => array:2 [ "nombre" => "C." "apellidos" => "Ortega Navarro" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S001425651930030X" "doi" => "10.1016/j.rce.2018.12.009" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S001425651930030X?idApp=WRCEE" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2254887419300761?idApp=WRCEE" "url" => "/22548874/0000021900000004/v1_201904260621/S2254887419300761/v1_201904260621/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S2254887419300505" "issn" => "22548874" "doi" => "10.1016/j.rceng.2018.12.007" "estado" => "S300" "fechaPublicacion" => "2019-05-01" "aid" => "1619" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Medicina Interna (SEMI)" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Rev Clin Esp. 2019;219:224" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "Correspondence" "titulo" => "Limitation of therapeutic effort in elderly patients" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "224" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Limitación del esfuerzo terapéutico en pacientes mayores" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "E. Ameneiros-Lago, C. Carballada-Rico, J.A. Garrido-Sanjuán" "autores" => array:3 [ 0 => array:2 [ "nombre" => "E." "apellidos" => "Ameneiros-Lago" ] 1 => array:2 [ "nombre" => "C." "apellidos" => "Carballada-Rico" ] 2 => array:2 [ "nombre" => "J.A." "apellidos" => "Garrido-Sanjuán" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0014256519300165" "doi" => "10.1016/j.rce.2018.12.004" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0014256519300165?idApp=WRCEE" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2254887419300505?idApp=WRCEE" "url" => "/22548874/0000021900000004/v1_201904260621/S2254887419300505/v1_201904260621/en/main.assets" ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "Correspondence" "titulo" => "Intravitreal bevacizumab: Is it exempt from adverse extraocular effects?" "tieneTextoCompleto" => true "saludo" => "Dear Editor," "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "225" "paginaFinal" => "226" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "M. Sánchez López, M.A. Navarro Puerto, I. Gutiérrez Morales" "autores" => array:3 [ 0 => array:4 [ "nombre" => "M." "apellidos" => "Sánchez López" "email" => array:1 [ 0 => "marinasanlop@gmail.com" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "*" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "M.A." "apellidos" => "Navarro Puerto" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "b" "identificador" => "aff0010" ] ] ] 2 => array:3 [ "nombre" => "I." "apellidos" => "Gutiérrez Morales" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "c" "identificador" => "aff0015" ] ] ] ] "afiliaciones" => array:3 [ 0 => array:3 [ "entidad" => "Medicina Familiar y Comunitaria, Hospital Universitario de Valme, Sevilla, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Unidad de Gestión Clínica de Medicina Interna, Hospital Universitario de Valme, Sevilla, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Unidad de Gestión Clínica de Cuidados Críticos y Urgencias, Hospital Universitario de Valme, Sevilla, Spain" "etiqueta" => "c" "identificador" => "aff0015" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Bevacizumab intravítreo, ¿está exento de efectos adversos extraoculares?" ] ] "textoCompleto" => "Bevacizumab is an antineoplastic drug that acts as a monoclonal antibody and binds to vascular endothelial growth factor (VEGF), a key component of vasculogenesis and angiogenesis, thereby inhibiting the binding of this factor to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2), located on the surface of endothelial cells. The neutralization of VEGF's biological activity produces a regression in tumor vascularization, inhibits tumor neovascularization and thereby inhibits tumor growth (breast, colon, non-small cell lung, kidney, ovarian, etc.).The use of bevacizumab has extended to other diseases with vascular proliferation, such as ocular disease (through intravitreal administration) and age-related macular degeneration, proliferative diabetic retinopathy, macular edema, retinopathy of prematurity<a class="elsevierStyleCrossRef" href="#bib0025">1</a> and even in individual cases of ocular melanoma.<a class="elsevierStyleCrossRef" href="#bib0030">2</a>The intravitreal use of bevacizumab is not approved according to its datasheet, because the compound has not been developed for this administration route.The most common adverse effects of bevacizumab when administered parenterally as an antineoplastic agent are similar to those observed with chemotherapy and can exacerbate them when combined with these chemotherapy agents. The most common adverse reactions include pancytopenia, anorexia, hyponatremia, peripheral sensory neuropathy, dysgeusia, ocular disorder, arterial hypertension, thromboembolism, rhinitis, dyspnea, diarrhea, nausea, vomiting, dermatitis, joint pain, myalgia, asthenia, mucositis and weight loss.<a class="elsevierStyleCrossRef" href="#bib0025">1</a>Individual cases and severe ocular adverse reactions have been reported after its intravitreal use, such as infectious endophthalmitis, intraocular inflammation (sterile endophthalmitis, uveitis, vitritis), retinal detachment, lacerations of the epithelial retinal pigments, increased intraocular pressure and intraocular hemorrhage (vitreous, retinal, conjunctival). Some of these reactions have caused vision loss to varying degrees, including permanent blindness.<a class="elsevierStyleCrossRef" href="#bib0035">3</a>After an intravitreal anti-VEGF treatment, reductions have been shown in the circulating VEGF concentration.<a class="elsevierStyleCrossRef" href="#bib0040">4</a> Nevertheless, systemic adverse reactions have been reported after the administration of VEGF, such as nonocular hemorrhaging and thromboembolism.<a class="elsevierStyleCrossRef" href="#bib0035">3</a>A recent study compared the pharmacokinetics of 3 monoclonal anti-VEGF antibodies after their intravitreal administration. Bevacizumab achieved the highest systemic concentrations compared with aflibercept and ranibizumab and therefore presented the largest number of adverse reactions.<a class="elsevierStyleCrossRef" href="#bib0040">4</a>We present a case in which we show the unusual potential adverse effects from the intravitreal administration of bevacizumab, effects not present in the consulted literature.The case involves a 77-year-old woman who was admitted to internal medicine for dyspnea. The patient's history included arterial hypertension, type 2 diabetes mellitus, paroxysmal atrial fibrillation and bilateral age-associated macular degeneration, treated with intravitreal bevacizumab 10 months earlier. Follow-up was conducted in internal medicine consultations due to anosmia and ageusia, without determining the cause. The patient was examined by the otorhinolaryngology department, who performed fibroscopy and computed tomography of the nasal fossae, with no pathological findings. Treatment was performed with acenocoumarol, furosemide, insulin, omeprazole, carvedilol and amlodipine.During the hospitalization in internal medicine and once the dyspnea and pneumonia had improved, the predominant symptoms were anosmia and ageusia, showing constitutional symptoms of anorexia secondary to the predominant symptoms.Faced with a ground-glass pattern in the computed tomography and mediastinal adenopathies, we conducted a broad study (tumor markers, fibrobronchoscopy and bronchoalveolar lavage, proteinogram, angiotensin-converting enzyme, serology) to rule out a solid neoplasm, a lymphoproliferative process, disease infiltration and sarcoidosis, the results of all of which were negative. After starting empiric treatment with corticosteroids, the adenopathies decreased in size considerably, the patient improved clinically, and the dyspnea ceased. Given this result and the patient's wishes, no further studies were performed.Due to persistent anosmia and ageusia, we conducted a review of the potential etiologies and management of these symptoms. We started treatment with clonazepam, with slight improvement but with an early withdrawal due to intolerance to clonazepam.Therefore, this case involves a patient with anosmia and ageusia secondary to the intravitreal administration of bevacizumab. We reached this conclusion after a broad study that resulted in no findings related to these symptoms and no other history that would explain them. There was also a clear temporal cause-and-effect relationship after the administration of bevacizumab and the development of symptoms.With the publication of this case, we wish to note the importance of keeping in mind the uncommon potential adverse effects, not described in the literature, related to the intravitreal administration of bevacizumab and assess the risk-benefit in terms of its administration and inform patients of the potential complications." "pdfFichero" => "main.pdf" "tienePdf" => true "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "Please cite this article as: Sánchez López M, Navarro Puerto MA, Gutiérrez Morales I. Bevacizumab intravítreo, ¿está exento de efectos adversos extraoculares? Rev Clin Esp. 2019;219:225–226." ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:4 [ 0 => array:3 [ "identificador" => "bib0025" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Ficha técnica bevacizumab. Available from: <a id="intr0010" class="elsevierStyleInterRef" href="https://ec.europa.eu/health/documents/community-register/2012/20120830124164/anx_124164_es.pdf">https://ec.europa.eu/health/documents/community-register/2012/20120830124164/anx_124164_es.pdf</a> [accessed 08.02.18]." ] ] ] 1 => array:3 [ "identificador" => "bib0030" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Growth of uveal melanoma following intravitreal bevacizumab" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "J.H. Francis" 1 => "J. Kim" 2 => "A. Lin" 3 => "R. Folberg" 4 => "S. Iyer" 5 => "D.H. Abramson" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1159/000450859" "Revista" => array:6 [ "tituloSerie" => "Ocul Oncol Pathol" "fecha" => "2017" "volumen" => "3" "paginaInicial" => "117" "paginaFinal" => "121" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28868282" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0035" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Complications in patients after intravitreal injection of bevacizumab" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C. Shima" 1 => "H. Sakaguchi" 2 => "F. Gomi" 3 => "M. Kamei" 4 => "Y. Ikuno" 5 => "Y. Oshima" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Acta Ophthalmol (Copenh)" "fecha" => "2008" "volumen" => "86" "paginaInicial" => "372" "paginaFinal" => "376" ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0040" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab and ranibizumab" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R.L. Avery" 1 => "A.A. Castellarin" 2 => "N.C. Steinle" 3 => "D.S. Dhoot" 4 => "D.J. Pieramici" 5 => "R. See" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/IAE.0000000000001493" "Revista" => array:6 [ "tituloSerie" => "Retina" "fecha" => "2017" "volumen" => "37" "paginaInicial" => "1847" "paginaFinal" => "1858" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28106709" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/22548874/0000021900000004/v1_201904260621/S2254887419300773/v1_201904260621/en/main.assets" "Apartado" => array:4 [ "identificador" => "71813" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Correspondence" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/22548874/0000021900000004/v1_201904260621/S2254887419300773/v1_201904260621/en/main.pdf?idApp=WRCEE&text.app=https://revclinesp.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2254887419300773?idApp=WRCEE"]

Revista Clínica Española (English Edition)

ISSN: 2254-8874

Revista Clínica Española published its first issue in 1940 and is the body of expression of the Spanish Society of Internal Medicine (SEMI).
The journal fully endorses the goals of updating knowledge and facilitating the acquisition of key developments in internal medicine applied to clinical practice. Revista Clínica Española is subject to a thorough double blind review of the received articles written in Spanish or English. Ten issues are published each year, including mostly originals, reviews and consensus documents.

Indexed in:

Current Contents / Clinical Medicine , JCR / SCI-Expanded, Index Medicus / Medline y Excerpta Medica / EMBASE

Subscribe:

Impact factor

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.

© Clarivate Analytics, Journal Citation Reports 2022

Impact factor 2023

2.3

Citescore

CiteScore measures average citations received per document published.

Citescore 2023

0.7

SJR

SRJ is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal's impact.

SJR 2023

0.162

SNIP

SNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field.

SNIP 2023

0.211

View more metrics

Open Access Option

Journal Information

Previous article | Next article

Lee este artículo en Español

Export reference

Download PDF

Purchase article

For the purchase of this article it is necessary to fill in the following form:

Name *

First surname *

Second surname

Email *

Address *

Number *

City *

Afganistan

Albania

Alemania

Andorra

Angola

Anguilla

Antartica

Antigua and barbuda

Antillas holandesas

Arabia saudita

Argelia

Argentina

Armenia

Aruba

Australia

Austria

Azerbaijan

Bahamas

Bahrain

Bangladesh

Barbados

Belarus

Belgica

Belice

Benin

Bermudas/antillas britanicas

Bhutan

Bolivia

Bosnia y herzegowina

Botswana

Brasil

Brunei darussalam

Bulgaria

Burkina faso

Burundi

Cabo verde

Camboya

Camerun

Canada

Chad

Chile

China

Chipre

Colombia

Comoros

Corea

Costa rica

Cote d´ivoire

Croacia

Cuba

Dinamarca

Djibouti

Dominica

East timor

Ecuador

Egipto

El salvador

Emiratos arabes unidos

Eritrea

Escocia

Eslovaquia

Eslovenia

España

Estados federados de micronesia

Estados unidos

Estonia

Etiopia

Fiji

Filipinas

Finlandia

Francia

Gabon

Gambia

Georgia

Ghana

Gibraltar

Grecia

Grenada

Groenlandia

Guadalupe

Guam

Guatemala

Guayana britanica

Guinea

Guinea ecuatorial

Guinea francesa

Guinea-bissau

Haiti

Holanda

Honduras

Hong kong

Hungria

India

Indonesia

Irak

Iran

Irlanda

Isla bouvet

Isla cocos (keeling)

Isla cook

Isla mauricio

Isla navidad

Isla norfolk

Islandia

Islas caiman

Islas falkland (malvinas)

Islas faroe

Islas georgia del sur y sandwich

Islas heard and mc donald

Islas marshall

Islas northern mariana

Islas salomon

Islas svalbard and jan mayen

Islas turks and caicos

Islas united states minor outlyi

Islas virgenes (britanicas)

Islas virgenes (u.s.a.)

Islas wallis and futuna

Israel

Italia

Jamaica

Japon

Jordania

Kazakhstan

Kenia

Kiribati

Kuwait

Kyrgyzstan

Lesoto

Letonia

Libano

Liberia

Libia arab jamahiriya

Liechtenstein

Lituania

Luxemburgo

Macao

Macedonia

Madagascar

Malasia

Malawi

Maldives

Mali

Malta

Marruecos

Martinica

Mauritania

Mayotte

Mexico

Monaco

Mongolia

Monserrat

Morocco

Mozambique

Myanmar

Namibia

Nauru

Nepal

Nicaragua

Niger

Nigeria

Niue

Noruega

Nueva caledonia

Nueva zelanda

Oman

Pakistan

Palau

Panama

Papua new guinea

Paraguay

Peru

Pitcairn

Polinesia francesa

Polonia

Portugal

Posesiones gran bretaña

Posesiones u.s.a.

Puerto rico

Qatar

Reino unido

Republica checa

Republica de africa central

Republica de cabo verde

Republica de congo

Republica de corea

Republica de moldova

Republica democratica de laos

Republica democratica del congo

Republica dominicana

Reunion

Ruanda

Rumania

Rusia

Sahara occidental

Saint kitts and nevis

Samoa

Samoa americana

San marino

San tomas y principe

San vincent and the grenadines

Santa lucia

Senegal

Serbia

Seychelles

Sierra leona

Singapur

Siria

Somalia

Sri lanka

St. helena

St. pierre and miquelon

Sudafrica

Sudan

Suecia

Suiza

Surinam

Swaziland

Tailandia

Taiwan republica de china

Tajikistan

Tanzania

Territorio de indias britanicas

Togo

Tokelau

Tonga

Trinidad and tobago

Tunisia

Turkmenistan

Turquia

Tuvalu

Ucrania

Uganda

Uruguay

Uzbekistan

Vanuatu

Vaticano

Venezuela

Vietnam

Yemen

Yugoslavia

Zambia

Zimbawe

Lebanon

Paises bajos

A coruña

Alava

Albacete

Alicante

Almeria

Asturias

Avila

Badajoz

Balears

Barcelona

Bizkaia

Burgos

Caceres

Cadiz

Cantabria

Castellon

Ceuta

Ciudad real

Cordoba

Cuenca

Girona

Granada

Guadalajara

Guipuzcoa

Huelva

Huesca

Jaen

La rioja

Las palmas

Leon

Lleida

Lugo

Madrid

Malaga

Melilla

Murcia

Navarra

Ourense

Palencia

Pontevedra

Salamanca

Segovia

Sevilla

Soria

Tarragona

Tenerife

Teruel

Toledo

Valencia

Valladolid

Zamora

Zaragoza

-- Not applicable --

Código postal *

Phone *

NIF o número identificativo *

I accept to receive information about Elsevier's special products and promotions by email

I accept to receive information about products and special promotions from Elsevier partners by email

I have read and understand the Privacy Policy and Terms and conditions and agree to be bound by all of its terms.

* Required fields

In addition to temporary access to the article, it will be sent by email.

Customer Support

Phone

Calls from Spain

932 415 960

Calls from abroad

+34 932 415 960

Hours from 9 a.m. to 6 p.m. except the months of July and August, which will be from 9 am to 3 pm.

Highlighted articles

Recommendations of the Spanish-Portuguese Internal Medicine services in the fight against climate change and environmental degradation

Publish in

Revista Clínica Española

Free access articles

The value of multi-modal ultrasound in the assessment of...

Rev Clin Esp. 2024;224:437-44

Adverse cardiovascular, obstetric and perinatal events...

Rev Clin Esp. 2024;224:337-45

How to detect non-institutionalized older patients at risk...

Rev Clin Esp. 2024;224:217-24

Revista Clínica Española (English Edition) is a member and subscribes the principles of, the Committee on Publication Ethics (COPE)
www.publicationethics.org.

Indexed in:

Follow us:

Subscribe:

Purchase article

Subscribe to our newsletter